[1] Scientific Backgroud:Discovery of cancer therapy by inhibition of negative immune regulation[EB/OL].(2018-10-1) https://www.nobelprize.org/prizes/medicine/2018/advanced-information/.
[2] Fisher D E. Apoptosis in cancer therapy:crossing the threshold[J]. Cell, 1994, 78(4):539-42.
[3] Lombard D B, Chua K F, Mostoslavsky R, et al. DNA repair, genome stability, and aging[J]. Cell, 2005, 120(4):497-512.
[4] Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J]. Nat Immunol, 2018,19(7):723-732.
[5] Cong J, Wang X, Zheng X, et al. Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression[J]. Cell Metab, 2018, 28(2):243-55 e5.
[6] Anderson A C, Joller N, Kuchroo V K. Lag-3, Tim-3, and TIGIT:Co-inhibitory Receptors with Specialized Functions in Immune Regulation[J]. Immunity, 2016, 44(5):989-1004.
[7] Pauken K E, Wherry E J. TIGIT and CD226:tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit[J]. Cancer Cell, 2014, 26(6):785-787.
[8] Tamada K, Harada M, Okamoto T, et al. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2[J]. Cancer Immunol Immunother, 1995, 41(6):339-347.
[9] Leach D R, Krummel M F, Allison J P. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science, 1996, 271(5256):1734-1736.
[10] Kwon E D, Hurwitz A A, Foster B A, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer[J]. Proc Natl Acad Sci U S A, 1997, 94(15):8099-10103.
[11] Chambers C A, Kuhns M S, Egen J G, et al. CTLA-4-mediated inhibition in regulation of T cell responses:mechanisms and manipulation in tumor immunotherapy[J]. Annu Rev Immunol, 2001, 19(1):565-594.
[12] Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895.
[13] Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes[J]. Int Immunol, 1996, 8(5):765-772.
[14] Nishimura H, Agata Y, Kawasaki A, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes[J]. Int Immunol, 1996, 8(5):773-780.
[15] Chen L, Ashe S, Brady W A, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4[J]. Cell, 1992, 71(7):1093-1102.
[16] Freeman G J, Long A J, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7):1027-1034.
[17] Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity[J]. Cancer Res, 2005, 65(3):1089-1096.
[18] Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells[J]. Int Immunol, 2005, 17(2):133-144.
[19] Seremet T, Planken S, Schwarze J K, et al. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma[J]. Melanoma Res, 2018, Epub ahead of print. |
